Characteristics | Cutaneous adverse reactions | SJS/TEN | |||||
---|---|---|---|---|---|---|---|
EMa (N = 122) | SJS/TEN (N = 132) | P value | Stevens–Johnson Syndrome (N = 73) | SJS–TEN overlapb (N = 18) | Toxic epidermal necrolysis (N = 41) | P value | |
Episodes as main diagnosis—n (%) | 34 (27.9) | 89 (66.4) | 45 (61.6) | 14 (77.8) | 30 (68.3) | ||
6-years incidence (per million inhabitants) | 12.2 | 13.2 | 7.3 | 1.8 | 4.1 | ||
Gender—n (%) | |||||||
Male | 43 (35.2) | 60 (45.5) | 0.098 | 34 (46.6) | 9 (50.0) | 17 (41.5) | 0.798 |
Female | 79 (64.8) | 72 (54.5) | 39 (53.4) | 9 (50.0) | 25 (58.5) | ||
Age (years) | |||||||
Median (percentile 25–75) | 63 (44–77) | 63 (45–75) | 0.903 | 64 (46–79) | 57 (34–72) | 65 (48–74) | 0.492 |
Comorbidities | |||||||
Hypertension | 39 (32.0) | 46 (34.8) | 0.627 | 29 (39.7) | 5 (27.8) | 12 (29.3) | 0.422 |
Diabetes | 19 (15.6) | 22 (16.7) | 0.813 | 13 (17.8) | 4 (22.2) | 5 (12.2) | 0.589 |
Heart failure | 10 (8.2) | 13 (9.8) | 0.647 | 8 (11.0) | 3 (16.7) | 2 (4.9) | 0.272 |
Chronic kidney disease | 12 (9.8) | 15 (11.4) | 0.693 | 7 (9.6) | 4 (22.2) | 4 (9.8) | 0.340 |
Liver disease | 11 (9.0) | 10 (7.6) | 0.677 | 4 (5.5) | 3 (16.7) | 3 (7.3) | 0.203 |
Acute toxic hepatitis | 7 (5.7) | 6 (4.5) | 0.882 | 2 (2.7) | 2 (11.1) | 2 (4.9) | 0.269 |
HIV | 2 (1.6) | 12 (9.1) | 0.009 | 8 (11.0) | 3 (16.7) | 1 (2.4) | 0.115 |
Length-of-stayc (days) | |||||||
Median (percentile 25–75) | 10 (5–20) | 15 (7–28) | 0.007 | 15 (7–23) | 23 (9–36) | 14 (7–28) | 0.456 |
In-hospital mortality—n (%) | 9 (7.4) | 32 (24.2) | < 0.001 | 12 (16.4) | 2 (11.1) | 18 (43.9) | 0.002 |